Serotonin Syndrome With the Concomitant Use of Triptans and SSRIs/Serotonergic Medications: Is It Time to Revisit FDA Warning?

MLA

Mansuri, Zeeshan, et al. “Serotonin Syndrome With the Concomitant Use of Triptans and SSRIs/Serotonergic Medications: Is It Time to Revisit FDA Warning?” Journal of Clinical Psychopharmacology, vol. 44, no. 2, Mar. 2024, pp. 199–200. EBSCOhost, https://doi.org/10.1097/JCP.0000000000001812.

APA

Mansuri, Z., Adnan, M., Shah, B., Trivedi, C., Vadukapuram, R., Patel, S., Yadav, G., Srinivas, S., Ansari, M., Makani, R., Baweja, R., & Reddy, A. (2024). Serotonin Syndrome With the Concomitant Use of Triptans and SSRIs/Serotonergic Medications: Is It Time to Revisit FDA Warning? Journal of Clinical Psychopharmacology, 44(2), 199–200. https://doi.org/10.1097/JCP.0000000000001812

Chicago

Mansuri, Zeeshan, Mahwish Adnan, Bhumika Shah, Chintan Trivedi, Ramu Vadukapuram, Shweta Patel, Garima Yadav, et al. 2024. “Serotonin Syndrome With the Concomitant Use of Triptans and SSRIs/Serotonergic Medications: Is It Time to Revisit FDA Warning?” Journal of Clinical Psychopharmacology 44 (2): 199–200. doi:10.1097/JCP.0000000000001812.